Numerous clinical trials have investigated the therapeutic potential of combining BTK inhibitors with other drugs for CNS lymphoma treatment, including chemotherapy agents, immune checkpoint inhibitors, PI3K/AKT/mTOR inhibitors, immunomodulatory imide drugs, and various multi‐agent combinations.16, 33. Here, AKT1 is linked to primary central nervous system lymphoma.